Lorazepam
Also known as: Ativan, Lorazepam Intensol, Loreev.
Wholesale (NADAC) cost for every strength and dosage form — the price pharmacies pay, published weekly by CMS. Not your out-of-pocket price.
Wholesale (NADAC) prices — every strength & form
| Strength | Form | NADAC / unit | Package | Class |
|---|---|---|---|---|
| 0.5 MG | Tablet | $0.033 / unit | — | Generic |
| 1 MG | Tablet | $0.037 / unit | — | Generic |
| 1 MG | Capsule ER | $14.26 / unit | — | Brand |
| 1.5 MG | Capsule ER | $14.24 / unit | — | Brand |
| 2 MG | Tablet | $0.070 / unit | — | Generic |
| 2 MG | Capsule ER | $14.23 / unit | — | Brand |
| 2 MG/ML | (unspecified) | $0.647 / mL | — | Generic |
| 2 MG/ML | Vial | $1.93 / mL† | — | Generic |
| 3 MG | Capsule ER | $14.23 / unit | — | Brand |
Wholesale (NADAC) — the price pharmacies pay, not your out-of-pocket price. Brand list prices fall after confidential rebates. † Package size not curated yet — priced per single unit/mL, not per full pen, inhaler, or vial. Liquids, creams, and sprays are priced per mL or gram; a typical package may be a bottle or tube (size not set yet).
NADAC week of 2026-07-01 · updated weekly · source CMS
Medicaid & Medicare spending · 2024
In 2024, Medicaid paid $25,520,712 gross for Lorazepam across 2,194,521 prescriptions (measured, national).
Medicare Part D EST spent an estimated ~$52,419,929 gross (retail pharmacy only; excludes Part B).
Gross program spending, before rebates — not what patients pay out of pocket. Brand net cost is materially lower after confidential rebates; generics are close to net.
Source: Medicaid SDUD 2024 · Medicare Part D 2024 · CMS